[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628508":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":11,"locations":23,"responsibleParty":42,"collaborators":11,"id":46,"slug":11,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":11,"enrollmentInfo":54,"targetDuration":11,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":11,"overallStatus":26,"whyStopped":11,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"General Hospital of Shenyang Military Region","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TCD group","EXPERIMENTAL",null,[13],"Device: Transcranial Doppler",{"label":15,"type":16,"description":11,"interventionNames":11},"Control group","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DEVICE","Transcranial Doppler","TCD treatment (1.6 MHz, 0.274 MPa) from femoral artery puncture until 30-60 minutes after procedure completion",[9],[24],{"facility":25,"status":26,"city":27,"state":11,"zip":28,"country":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Department of Neurology, General Hospital of Northern Theater Command","RECRUITING","Shenyang","110016","China",{"type":31,"coordinates":32},"Point",[33,34],123.43278,41.79222,{"lat":34,"lon":33},[37],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"Hui-Sheng Chen, Ph.D.","CONTACT","+86 13352452086","chszh@aliyun.com",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Hui-Sheng Chen","Director","100628508",false,"NCT07462546","Transcranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS)","Transcranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS): A Prospective, Randomized Controlled, Blind Endpoint, Single-Center Study","Inclusion Criteria:\n\n* Age ≥ 40 years old;\n* Patients with severe stenosis of the internal carotid artery;\n* Planned for carotid artery stent;\n* Modified Rankin Scale score ≤ 2;\n* The subject has adequate temporal bone windows to undergo TCD, and the blood flow signal of the middle cerebral artery is detectable.;\n* Signed informed consent by patient or their legally authorized representative.\n\nExclusion Criteria:\n\n* Comorbid conditions with severe infections or severe diseases of the liver, kidney, hematopoietic system, endocrine system, etc.;\n* Occurrence of intracranial hemorrhage (cerebral parenchymal hemorrhage, subarachnoid hemorrhage, subdural\u002Fepidural hemorrhage) within 90 days prior to enrollment;\n* Severe hematological disorders or significant coagulation abnormalities;\n* Pregnant or breastfeeding women;\n* Participation in another clinical trial within the past 3 months or ongoing participation;\n* Any other circumstances deemed by the investigator as unsuitable for participation in this clinical study.","ALL","40 Years",{"count":55,"type":56},232,"ESTIMATED","INTERVENTIONAL",[59],"NA","Carotid artery stenting (CAS) prevents stroke but carries risks of perioperative cerebral embolism. Transcranial Doppler (TCD) ultrasound can detect microemboli during CAS and may offer therapeutic benefits through ultrasound-enhanced thrombolysis. Trials like SONOBUSTER and SONOBIRDIE suggest TCD reduces new brain infarctions during carotid procedures. The TCD-ICAS trial will investigate whether TCD application during and after CAS reduces perioperative cerebral emboli and improves outcomes.",[62],"Artery Stenosis","2026-03-24",{"date":65,"type":66},"2026-03-25","ACTUAL",{"date":63,"type":66},{"date":69,"type":56},"2026-11-30",{"name":5,"class":6},1]